DDInter513 DDInter704
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Dexamethasone {u} (Compound) palliates {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Everolimus
Dexamethasone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Dexamethasone {u} (Compound) upregulates {v} (Gene) CDK5R1
CDK5R1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Dexamethasone {u} (Compound) downregulates {v} (Gene) DLX2
DLX2 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Dexamethasone {u} (Compound) downregulates {v} (Gene) FHL2
FHL2 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Dexamethasone {u} (Compound) upregulates {v} (Gene) BLMH
BLMH {u} (Gene) is downregulated by {v} (Compound) Everolimus
Dexamethasone {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Everolimus
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Dexamethasone {u} (Compound) palliates {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Dexamethasone (Compound) palliates kidney cancer (Disease) and kidney cancer (Disease) is treated by Everolimus (Compound)
Dexamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Dexamethasone (Compound) upregulates CDK5R1 (Gene) and CDK5R1 (Gene) is upregulated by Everolimus (Compound)
Dexamethasone (Compound) downregulates DLX2 (Gene) and DLX2 (Gene) is upregulated by Everolimus (Compound)
Dexamethasone (Compound) downregulates FHL2 (Gene) and FHL2 (Gene) is downregulated by Everolimus (Compound)
Dexamethasone (Compound) upregulates BLMH (Gene) and BLMH (Gene) is downregulated by Everolimus (Compound)
Dexamethasone (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Everolimus (Compound)
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Dexamethasone (Compound) palliates kidney cancer (Disease) and kidney cancer (Disease) is treated by Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)